Skip To Main Content
Xi-Ying Wang on Muck Rack

Xi-Ying Wang

As seen in: Nature, Canadian Journal of Infectious Diseases & Medical Microbiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xi-Ying

Contact Xi-Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Human umbilical cord mesenchymal stromal cells therapy for neuromyelitis optica spectrum disorder: a phase 1/2a trial

|
By Xiao-Ying Yao, Zhong-jiao Lu, Nan Zhao, Li Xie, Yi-Shu Wang, Ying Zhang, Yan Lin, Ye Deng, Xi-Ying Wang, Yi Chen, He Zhu, Lin-Feng Li, Hui-Ming Xu, Jie Ding, Yi-Fan Wu, Ze Wang, Ya-Ying Song, Kan Wang, Yan Zhou, Quan Guo, Bi-yun Qian, Yang-Tai Guan, Chun-Ran Xue, Xu-Zhong Pei, Meng-Ze Zhang, Wen-Bin Wan, Hui-Ying Qiu, Yu-Yan Jin, Li-Ping Ni, Jia-Li Yan, Jia-Hui Xue, Yu-Fang Mei, Hao-Jun Yu
| Nature Verified
Abstract Current treatments for neuromyelitis optica spectrum disorder (NMOSD) highlight recurrence management, while little attention is paid to the relief of residual neurological dysfunction. Here we aimed to evaluate the safety and efficacy of human umbilical cord-derived mesenchymal stromal cells (hUC-MSCs) in reducing relapses and mitigating neurological impairments.
Open in Who Shared Issue with article?
See all 1 licensed articles (2 Total)